Patient-centered care of de Quervain’s disease

Abstract

Purpose

To test the hypothesis that most patients that elect symptomatic treatment of de Quervain’s disease experience symptom resolution.

Materials and methods

Eighty-three of 314 (26%) patients that elected initial symptomatic treatment of de Quervain’s disease responded to a mail survey inquiring about symptom resolution, symptom duration, subsequent opinions and treatments, final impressions and comments.

Results

Seventy-five respondents (90.4%) reported resolution of the pain, including 58 of the 61 (95%) respondents that elected neither corticosteroid injection nor surgery. Among patients with symptom resolution without injection or surgery 48 of 58 (83%) recalled symptoms for fewer than 12 months. The differences in reported average time to symptom resolution were not statistically significant between patients that elected or did not elect a corticosteroid injection.

Conclusions

Considered in the light of important limitations of this data including the reliance on patient recall and the limited response rate to the survey, the data are still intriguing. At least in one surgeon’s practice, most informed patients initially elect symptomatic treatment, and most experience symptom resolution within one year.

Keywords

DeQuervain’s syndrome - tendinosis - patient-centered care - shared decision making

• References

• 1 Christie BG. Local hydrocortisone in de Quervain’s disease. BMJ 1955; 1 ((4929)) 1501-1503
• 2 Piver JD, Raney RB. De Quervain’s tendovaginitis. Am J Surg Mar 1952; 83 ((5)) 691-694
• 3 Lamphier TA, Long NG, Dennehy T. De Quervain’s disease: an analysis of 52 cases. Ann Surg Dec 13 1953; 8 ((6)) 832-841
• 4 McKenzie JM. Conservative treatment of de Quervain’s disease. Br Med J Dec 16 1972; 4 ((5841)) 659-660
• 5 Sawaizumi T, Nanno M, Ito H. De Quervain’s disease: efficacy of intra-sheath triamcinolone injection. Int Orthop Apr 2007; 31 ((2)) 265-268
• 6 Capasso G, Testa V, Maffulli N et al Surgical release of de Quervain’s stenosing tenosynovitis postpartum: can it wait?. Int Orthop 2002; 26 ((1)) 23-25
• 7 Avci S, Yilmaz C, Sayli U. Comparison of nonsurgical treatment measures for de Quervain’s disease of pregnancy and lactation. J Hand Surg [Am] Mar 2002; 27 ((2)) 322-324
• 8 Sakai N. Selective corticosteroid injection into the extensor pollicis brevis tenosynovium for de Quervain’s disease. Orthopedics Jan 2002; 25 ((1)) 68-70
• 9 Rankin ME, Rankin EA. Injection therapy for management of stenosing tenosynovitis (de Quervain’s disease) of the wrist. J Natl Med Assoc Aug 1998; 90 ((8)) 474-476
• 10 Zingas C, Failla JM, Van Holsbeeck M. Injection accuracy and clinical relief of de Quervain’s tendinitis. J Hand Surg [Am] Jan 1998; 23 ((1)) 89-96
• 11 Weiss AP, Akelman E, Tabatabai M. Treatment of de Quervain’s disease. J Hand Surg [Am] Jul 1994; 19 ((4)) 595-598
• 12 Anderson BC, Manthey R, Brouns MC. Treatment of De Quervain’s tenosynovitis with corticosteroids. A prospective study of the response to local injection. Arthritis Rheum Jul 1991; 34 ((7)) 793-798
• 13 Richie 3rd CA, Briner Jr WW. Corticosteroid injection for treatment of de Quervain’s tenosynovitis: a pooled quantitative literature evaluation. J Am Board Fam Pract Mar-Apr 2003; 16 ((2)) 102-106
• 14 Lane LB, Boretz RS, Stuchin SA. Treatment of de Quervain’s disease:role of conservative management. J Hand Surg [Br] Jun 2001; 26 ((3)) 258-260